Jonathan I. Silverberg, M.D., Ph.D., M.P.H., from the George Washington University School of Medicine and Health Sciences in Washington, D.C., and colleagues examined the relationship between lebrikizumab serum concentration levels and sustained clinical response after treatment cessation among lebrikizumab responders who discontinued treatment. Click here to know more.
